Thomson Reuters

Science

Newport Premium TM (for Innovators), building on the heritage of Newport Vision CI, is the most advanced competitive intelligence, business development and global active pharmaceutical ingredient (API) sourcing system from Thomson Reuters, the industry authority on the global generics market.

Created specifically for demanding professionals in innovator, biotech, specialty and niche-brand pharmaceutical companies, it ensures you don’t miss the developing generic competition that can impact your sales, the licensing opportunity that can build on your strengths, or the outsourcing opportunity that can help you free up your manufacturing capacity.

Built on more than a decade’s experience supplying solutions to meet critical business challenges in competitive intelligence, lifecycle management and brand management, Newport products are used by more than 80% of the world’s top innovators and biotechs.

Overview
What's Included
Optional Modules
Testimonials

With Newport Premium (for Innovators), you can:

Identify the likely source, timing and impact of generic competition on your branded products.
Detect and interpret the earliest signs of alternative form and polymorph development and API manufacture.
Quickly assess competitive dynamics for products in your portfolio.
Monitor generic competition for your competitors’ products.
Assess likely generic competitors and API suppliers by analyzing worldwide API consumption.
Evaluate strategies based on available routes of synthesis and kilogram API consumption data and trends.
Improve planning of development pipelines.
Adjust sales and revenue forecasting based on the timing and extent of future generic competition.
Spot potential patent challenges early and track them as they develop into litigation
Formulate IP protection strategies at the earliest opportunity.
Gather all the facts, before you hire costly specialist investigative firms and engage outside counsel.
Identify likely primary or backup suppliers of APIs.
Identify reliable, lower-cost, alternative or exclusive API sources for existing products.
Profile worldwide business partners for alliances, supply, out-licensing and manufacture.
Identify and evaluate global niche brands and candidate products for acquisition or licensing.

Why choose Newport Premium (for Innovators)?

Unique strategic intelligence. Newport Premium incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Reuters. It continually tracks, monitors and expertly analyzes ongoing developments in more than 40,000 launched products and 20,000 companies operating in the global pharmaceutical market.
Sophisticated targeting capabilities. Newport Premium can help you to identify, profile and evaluate licensing, acquisition and partnership opportunities in launched and approved products worldwide. You can discover the niche opportunities that match your strategic needs and unique strengths in research, sales or marketing.
Outsourcing support. Newport Premium incorporates intelligence on thousands of active ingredient manufacturers and dose companies, allowing you to make sophisticated decisions about potential partnering opportunities, whether you are looking to outsource manufacturing or marketing activities.
Proven business value. In use for many years at more than 80% of the world’s leading innovator pharmaceutical and biotech companies.

Our generic intelligence for innovators is also available in less extensive configurations. To find out more about Newport Global™ (formerly known as Newport Vision CI) or Newport Sourcing™ (formerly known as Newport Vision Sourcing), please contact us.

Product Intelligence

Unique, early API manufacturing intelligence for 7,000 active ingredients.
Regulatory filings, such as US and Japanese DMFs, Certificates of Suitability, Indian and Chinese Import Registrations, US DEA registration notices.
Two years of regional sales and consumption data, worldwide launch, and pack price data for 40,000 launched products containing over 10,000 different active ingredients. 1
US market share breakdown by dose form and strength.
US Orange Book, EU centralized procedure, and European first market authorization data.
Labeling and prescribing data for more than 1,500 unique products.
Chemical structure diagrams for thousands of products.
Routes of synthesis, including intermediates and reagents with patent and literature references for 3000 products. 2
Powerful indexing and searching of products according to FDA approved indication and technology class.
Proprietary analytics

Company Intelligence

Profiles of more than 25,000 companies and corporate groups, including subsidiaries, finished dose launches, US approvals, regulatory filings, APIs manufactured, inspections by the US FDA and other regulatory agencies, and Warning Letters.
Company key financial indicators and sales forecasts
Proprietary analytics and company ratings

Patents

Worldwide patent families and individual patents for more than 90 countries.
Comprehensive Supplementary Protection Certificate (SPC) data for Europe. 3
Projected loss of exclusivity dates for US, European and Japanese markets.
Paragraph IV patent challenges commentaries, including company identities, FTF and status of litigation for more than 250 products.

Current Awareness

Alerting on key changes in products and companies, including new regulatory filings, approvals, and patent challenges.
Real-time news regarding products and companies. 4
Reports on key conferences affecting the generics industry.

1 IMS Health

2 Prous Science, a Thomson Reuters business

3 Cabinet Alice de Pastors

4 AcquireMedia

Newport Phase III Drugs Module PDF Intelligence on products still in phase III clinical trials or going through registrations.

Newport Generic Deals Module PDF Thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.

Newport US Market Share Module PDF In August 2010, we will launch the Newport US Market Share Module which covers 10 years of product market share history that can be analyzed by dose form, strength, manufacturer, and brand vs. generic. This module integrates seamlessly with Newport Global or Newport Premium base systems, considerably enhancing the visibility of industry dynamics and insight into the U.S. pharmaceutical market.

Newport Biologics Module PDF In March 2011, we will launch the Newport Biologics Module which contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is U.S. BLA (Biologics License Application) data for drugs approved through this regulatory route.